{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:36:14Z","timestamp":1792622174961,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007002","name":"Small Business Innovative Research and Small Business Technology Transfer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.10.049","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T01:50:34Z","timestamp":1572659434000},"page":"644-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Co-administration of tecovirimat and ACAM2000\u2122 in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge"],"prefix":"10.1016","volume":"38","author":[{"given":"Andrew T.","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aklile","family":"Berhanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine B.","family":"Bigger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Prigge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Silvera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Grosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.10.049_b0005","series-title":"Proceedings of the Royal Society of London Series B Biological Sciences","first-page":"199","article-title":"Smallpox Eradication","author":"Henderson","year":"1977"},{"key":"10.1016\/j.vaccine.2019.10.049_b0010","article-title":"Challenges and Achievements in Prevention and Treatment of Smallpox","volume":"6","author":"Melamed","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2019.10.049_b0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clindermatol.2005.11.009","article-title":"The history of smallpox","volume":"24","author":"Geddes","year":"2006","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.vaccine.2019.10.049_b0020","first-page":"279","article-title":"The world's last endemic case of smallpox: surveillance and containment measures","volume":"58","author":"Deria","year":"1980","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.10.049_b0025","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1001\/jama.1978.03290180065033","article-title":"The conquest of smallpox","volume":"240","author":"Barclay","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.10.049_b0030","series-title":"Working Group on Civilian Biodefense","first-page":"2127","article-title":"Smallpox as a biological weapon: medical and public health management","author":"Henderson","year":"1999"},{"key":"10.1016\/j.vaccine.2019.10.049_b0035","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM198011273032204","article-title":"The confirmation and maintenance of smallpox eradication","volume":"303","author":"Breman","year":"1980","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2019.10.049_b0040","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2406.180017","article-title":"Reemergence of Human Monkeypox in Nigeria, 2017","volume":"24","author":"Yinka-Ogunleye","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.049_b0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fpubh.2018.00241","article-title":"Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans","volume":"6","author":"Sklenovska","year":"2018","journal-title":"Front Public Health."},{"key":"10.1016\/j.vaccine.2019.10.049_b0050","unstructured":"BARDA. Smallpox Antiviral for the Strategic National Stockpile. 2009. p. Request for Proposal."},{"key":"10.1016\/j.vaccine.2019.10.049_b0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fvl.11.27","article-title":"Development of the small-molecule antiviral ST-246 as a smallpox therapeutic","volume":"6","author":"Grosenbach","year":"2011","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2019.10.049_b0060","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3390\/v2112409","article-title":"Development of ST-246(R) for treatment of poxvirus infections","volume":"2","author":"Jordan","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.10.049_b0065","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.10.049_b0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-50-1-89","article-title":"Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia","volume":"50","author":"Payne","year":"1980","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.10.049_b0075","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.10.049_b0080","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.00879-06","article-title":"Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2019.10.049_b0085","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification","volume":"53","author":"Jordan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2019.10.049_b0090","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1128\/AAC.00977-13","article-title":"Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox)","volume":"57","author":"Mucker","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2019.10.049_b0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2008.03.005","article-title":"Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model","volume":"79","author":"Nalca","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2019.10.049_b0100","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/infdis\/jiy326","article-title":"Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques","volume":"218","author":"Russo","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.049_b0105","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004913.pub2","article-title":"Vaccines for preventing smallpox","author":"Metzger","year":"2007","journal-title":"Cochrane Database of Syst Rev"},{"key":"10.1016\/j.vaccine.2019.10.049_b0110","series-title":"Smallpox and its eradication","first-page":"539","article-title":"Ladnyi Smallpox vaccine and vaccination in the intensified smallpox eradication programme","author":"Fenner","year":"1988"},{"key":"10.1016\/j.vaccine.2019.10.049_b0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile","volume":"4","author":"Nalca","year":"2010","journal-title":"Drug Des Develop Therapy"},{"key":"10.1016\/j.vaccine.2019.10.049_b0120","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1371\/journal.pmed.0030272","article-title":"Frequency of adverse events after vaccination with different vaccinia strains","volume":"3","author":"Kretzschmar","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.vaccine.2019.10.049_b0125","first-page":"ofv040","article-title":"Safety and Immunogenicity of modified vaccinia ankara-bavarian nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. open forum","volume":"2","author":"Overton","year":"2015","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.049_b0130","first-page":"1","article-title":"Clinical guidance for smallpox vaccine use in a postevent vaccination program","volume":"64","author":"Petersen","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2019.10.049_b0135","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1086\/378357","article-title":"Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis","volume":"188","author":"Massoudi","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.049_b0140","series-title":"Geneva, Switzerlans: World Health Organization","first-page":"1","article-title":"The clinical features of smallpox. smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.vaccine.2019.10.049_b0145","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1016\/j.vaccine.2013.08.039","article-title":"The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data","volume":"31","author":"Keckler","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.049_b0150","unstructured":"USFDA. Product Development Under the Animal Rule, Guidance for Industry. Rockville, MD: United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research\/Center for Biologics Evaluation and Research; 2015."},{"key":"10.1016\/j.vaccine.2019.10.049_b0155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcpa.2012.06.007","article-title":"Comparative pathology of smallpox and monkeypox in man and macaques","volume":"148","author":"Cann","year":"2013","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.vaccine.2019.10.049_b0160","unstructured":"Council NR. Guide for the care and use of laboratory animals. Eighth ed: National Academies Press; 2011."},{"key":"10.1016\/j.vaccine.2019.10.049_b0165","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1128\/JCM.42.2.601-609.2004","article-title":"Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms","volume":"42","author":"Kulesh","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.10.049_b0170","series-title":"Smallpox and its eradication","first-page":"302","article-title":"Developments in vaccination and control between 1900 and 1966","author":"Fenner","year":"1988"},{"key":"10.1016\/j.vaccine.2019.10.049_b0175","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1086\/498155","article-title":"Reemergence of monkeypox: prevalence, diagnostics, and countermeasures","volume":"41","author":"Nalca","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.049_b0180","doi-asserted-by":"crossref","first-page":"e55808","DOI":"10.1371\/journal.pone.0055808","article-title":"Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals","volume":"8","author":"Duraffour","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.10.049_b0185","unstructured":"Organization WH. WHO Advisory committee on variola virus research: report of the nineteenth meeting, 1-2 November 2017, Geneva, Switzerland. World Health Organization; 2018."},{"key":"10.1016\/j.vaccine.2019.10.049_b0190","doi-asserted-by":"crossref","unstructured":"Ratto-Kim S, Yoon I-K, Paris RM, Excler J-L, Kim JH, O'Connell RJ. The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. Frontiers in immunology. 2018;9:1397.","DOI":"10.3389\/fimmu.2018.01397"},{"key":"10.1016\/j.vaccine.2019.10.049_b0195","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1586\/14760584.7.8.1225","article-title":"Smallpox vaccines for biodefense: need and feasibility","volume":"7","author":"Artenstein","year":"2008","journal-title":"Expert review of vaccines."},{"key":"10.1016\/j.vaccine.2019.10.049_b0200","unstructured":"Centers for Disease Control A, GA. Smallpox: Bioterrorism Response Planning. Available at: https:\/\/www.cdc.gov\/smallpox\/bioterrorism-response-planning\/index.html."},{"key":"10.1016\/j.vaccine.2019.10.049_b0205","first-page":"492","article-title":"Complications of vaccination against smallpox","volume":"76","author":"Greenberg","year":"1948","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.vaccine.2019.10.049_b0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(03)00008-1","article-title":"Pathogenesis and potential antiviral therapy of complications of smallpox vaccination","volume":"58","author":"Bray","year":"2003","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2019.10.049_b0215","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.vaccine.2007.11.095","article-title":"Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination","volume":"26","author":"Grosenbach","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.049_b0220","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.vaccine.2010.10.039","article-title":"Impact of ST-246(R) on ACAM2000 smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice","volume":"29","author":"Berhanu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.049_b0225","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1128\/AAC.00208-15","article-title":"Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection","volume":"59","author":"Berhanu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2019.10.049_b0230","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.1972.21.214","article-title":"A prospective study of serum antibody and protection against smallpox","volume":"21","author":"Mack","year":"1972","journal-title":"American J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.10.049_b0235","first-page":"307","article-title":"The minimum protective level of antibodies in smallpox","volume":"52","author":"Sarkar","year":"1975","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.10.049_b0240","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"Huggins","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.vaccine.2019.10.049_b0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/bsp.2012.0037","article-title":"The role of vaccination, antiorthopoxvirus drug, and social cooperativity in a mathematical model of smallpox control","volume":"11","author":"Finin","year":"2013","journal-title":"Biosecur Bioterror"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1931429X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1931429X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:38:10Z","timestamp":1759401490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1931429X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X1931429X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-administration of tecovirimat and ACAM2000\u2122 in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}